These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 1989661)

  • 1. Characterisation of adriamycin- and amsacrine-resistant human leukaemic T cell lines.
    Snow K; Judd W
    Br J Cancer; 1991 Jan; 63(1):17-28. PubMed ID: 1989661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues.
    Finlay GJ; Baguley BC; Snow K; Judd W
    J Natl Cancer Inst; 1990 Apr; 82(8):662-7. PubMed ID: 2157028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
    Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
    Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
    Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
    Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
    Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further characterization of drug-sensitivity and cross-resistance profiles of cloned cell lines of Adriamycin-sensitive and -resistant P388 leukemia.
    Seneviratne C; Goldenberg GJ
    Cancer Commun; 1989; 1(1):21-7. PubMed ID: 2640153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
    Granzen B; Graves DE; Baguley BC; Danks MK; Beck WT
    Oncol Res; 1992; 4(11-12):489-96. PubMed ID: 1363724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
    Goldenberg GJ; Wang H; Blair GW
    Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
    Matsumoto Y; Takano H; Nagao S; Fojo T
    Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposide.
    Danks MK; Schmidt CA; Deneka DA; Beck WT
    Cancer Commun; 1989; 1(2):101-9. PubMed ID: 2561733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.
    Potmesil M; Hsiang YH; Liu LF; Bank B; Grossberg H; Kirschenbaum S; Forlenza TJ; Penziner A; Kanganis D
    Cancer Res; 1988 Jun; 48(12):3537-43. PubMed ID: 2836060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological characterization of multidrug-resistant human colon carcinoma sublines induced/selected by two methods.
    Yang LY; Trujillo JM
    Cancer Res; 1990 Jun; 50(11):3218-25. PubMed ID: 2334917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells.
    de Tinguy-Moreaud E; Pourquier P; Montaudon D; Robert J
    Anticancer Res; 1994; 14(1A):99-103. PubMed ID: 8166463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A lack of detectable modification of topoisomerase II activity in a series of human tumor cell lines expressing only low levels of etoposide resistance.
    Hill BT; Whelan RD; Hosking LK; Shellard SA; Hinds MD; Mayes J; Zwelling LA
    Int J Cancer; 1991 Apr; 47(6):899-902. PubMed ID: 1849124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional down-regulation of c-myc expression in an erythroleukemic cell line, K562, and its doxorubicin-resistant variant by two topoisomerase II inhibitors, doxorubicin and amsacrine.
    Clary A; Larrue A; Pourquier P; Robert J
    Anticancer Drugs; 1998 Mar; 9(3):245-54. PubMed ID: 9625435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further characterization of two distinct adriamycin-resistant sublines from LoVo human colon carcinoma cells.
    Yang LY; Trujillo JM; Su YZ
    Anticancer Res; 1992; 12(2):473-9. PubMed ID: 1349796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.
    Baguley BC; Holdaway KM; Fray LM
    J Natl Cancer Inst; 1990 Mar; 82(5):398-402. PubMed ID: 2154584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line.
    de Jong S; Zijlstra JG; de Vries EG; Mulder NH
    Cancer Res; 1990 Jan; 50(2):304-9. PubMed ID: 1967222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.